A comprehensive view of Non-Vaccine Biologics. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA clears Bristol Myers Squibb’s Breyanzi lisocabtagene maraleucel cell therapy to treat large B-cell lymphoma in patients not eligible for stem cell transplant; drug uses genetically modified immune cells that fight cancer

Global regenerative medicine market expected to grow to US$83.19B by 2030, with CAGR growth of 23.4% from 2021 to 2030; growth to be driven by rise in chronic diseases and trauma emergencies, increasing adoption of stem cell technology and nanotechnology

Cell, gene therapy firm 4basebio collaborating with University of Alabama, Teesside University, to develop treatment for neurofibromatosis Type 1 that causes tumor growth on nerves; 4basebio to develop non-viral Hermes vector, hpDNA sequence as payload

Coeptis Therapeutics receives exclusive option from University of Pittsburgh to license three chimeric antigen receptor T cell technologies that target hematologic, solid tumors; deal includes pre-clinical programs involving breast and ovarian cancer

Ricoh acquires majority stake in biotechnology firm Elixirgen Scientific to accelerate mRNA and personalized drug discovery using Elixirgen’s IPS cell technology; companies to start business predicting drug responses, disease mechanisms using AI

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count